Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways.
Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways.
复制标题
接种SARS-CoV-2疫苗后的凝血病可能源于SARS-CoV-2刺突蛋白和腺病毒载体触发的信号通路的共同作用。
DOI：
10.3390/ijms221910791
复制
发表时间：
2021-10-06
影响因子：
5.6
通讯作者：
Kircheis R
中科院分区：
文献类型：
--
作者：
Kircheis R
新型冠状病毒SARS-CoV-2导致全球大流行，全球感染率达到6位数，每天有数千人死亡。为了阻止SARS-CoV-2感染的传播，正在作出巨大努力，实现免疫接种的高覆盖率，以达到群体免疫。几种基于mRNA、病毒载体或灭活SARS-CoV-2病毒的SARS-CoV-2疫苗已获批准并正在全球范围内应用。然而，最近报道了与血小板减少症相关的通常非常罕见的血栓类型的数量增加，特别是在Astra Zeneca的腺病毒载体疫苗ChAdOx1 nCoV-19的背景下。这些副作用的统计流行率似乎与这种特定的疫苗类型有关，即基于腺病毒载体的疫苗，但确切的分子机制仍不清楚。本综述将现有的分子和细胞机制的数据和假设总结为一个综合假设，表明凝血病变，包括血栓形成、血小板减少和其他相关副作用，与疫苗中两种成分（即刺突抗原和腺病毒载体）与先天和免疫系统的相互作用有关，在某些情况下可以模仿有限的COVID-19病理图像。
Novel coronavirus SARS-CoV-2 has resulted in a global pandemic with worldwide 6-digit infection rates and thousands of death tolls daily. Enormous efforts are undertaken to achieve high coverage of immunization to reach herd immunity in order to stop the spread of SARS-CoV-2 infection. Several SARS-CoV-2 vaccines based on mRNA, viral vectors, or inactivated SARS-CoV-2 virus have been approved and are being applied worldwide. However, the recent increased numbers of normally very rare types of thromboses associated with thrombocytopenia have been reported, particularly in the context of the adenoviral vector vaccine ChAdOx1 nCoV-19 from Astra Zeneca. The statistical prevalence of these side effects seems to correlate with this particular vaccine type, i.e., adenoviral vector-based vaccines, but the exact molecular mechanisms are still not clear. The present review summarizes current data and hypotheses for molecular and cellular mechanisms into one integrated hypothesis indicating that coagulopathies, including thromboses, thrombocytopenia, and other related side effects, are correlated to an interplay of the two components in the vaccine, i.e., the spike antigen and the adenoviral vector, with the innate and immune systems, which under certain circumstances can imitate the picture of a limited COVID-19 pathological picture.
登录
查看更多内容
影响因子：
15.8
作者：
Goldman M;Hermans C
通讯作者：
Hermans C
影响因子：
12.3
作者：
Almuqrin A;Davidson AD;Williamson MK;Lewis PA;Heesom KJ;Morris S;Gilbert SC;Matthews DA
通讯作者：
Matthews DA
影响因子：
46.9
作者：
Chua, Robert Lorenz;Lukassen, Soeren;Eils, Roland
通讯作者：
Eils, Roland
影响因子：
158.5
作者：
Ackermann, Maximilian;Verleden, Stijn E.;Jonigk, Danny
通讯作者：
Jonigk, Danny
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group